vTv Therapeutics (NASDAQ:VTVT) Stock Keeps “Buy” Rating at BTIG Research

vTv Therapeutics (NASDAQ:VTVT – Get Free Report)‘s stock had its “buy” rating restated by BTIG Research in a report issued on Wednesday, Benzinga reports. They presently have a $57.00 price target on the biotechnology company’s stock. BTIG Research’s price target suggests a potential upside of 101.48% from the company’s previous close.

VTVT has been the subject of a number of other research reports. Lifesci Capital upgraded vTv Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 2nd. HC Wainwright lowered their price objective on vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Zacks Research raised vTv Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, September 7th. Weiss Ratings lowered vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Finally, Wall Street Zen upgraded vTv Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 3rd. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $55.83.

Get vTv Therapeutics alerts:

Check Out Our Latest Stock Analysis on VTVT

vTv Therapeutics Stock Performance

Shares of vTv Therapeutics stock traded up $0.06 during trading hours on Wednesday, reaching $28.29. The company’s stock had a trading volume of 3,654 shares, compared to its average volume of 53,434. The company has a market capitalization of $111.46 million, a P/E ratio of -26.69 and a beta of 0.21. The stock’s fifty day simple moving average is $31.90 and its two-hundred day simple moving average is $33.55. vTv Therapeutics has a one year low of $19.50 and a one year high of $44.00.

vTv Therapeutics (NASDAQ:VTVT – Get Free Report) last posted its earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.08). As a group, research analysts forecast that vTv Therapeutics will post -2.35 earnings per share for the current year.

About vTv Therapeutics

(Get Free Report)

vTv Therapeutics, Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule medicines for chronic diseases. The company’s research has primarily addressed metabolic and neurological disorders, including diabetes and Alzheimer’s disease.

vTv’s development portfolio has included cadisegliatin (also known as TTP399), an oral, liver-selective glucokinase activator being studied as a potential treatment for type 1 diabetes, and azeliragon, an investigational drug designed to inhibit the receptor for advanced glycation end products (RAGE) in Alzheimer’s disease.

Featured Stories

• Five stocks we like better than vTv Therapeutics
• Don’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could Deepen
• Birkenstock’s Strong Growth Creates a Buying Opportunity
• High Voltage Returns: Navitas Rewires AI Data Centers
• Quantum BioPharma’s Phase 2 Shows Where Biotech Value Actually Gets Built

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.